Sign In
Buy BDPT
$0.0046
+0.0012 (+35.29%)
At Close: Jun 22, 2026
Perform. Repair. Repeat. — A stimulant-free, dual-phase platform built on the principle that cognitive excellence depends as much on what the brain does overnight as on what it achieves during the d
BioAdaptives, Inc. Launches MyndRenew™ to Complete the 24-Hour Brain Performance Cycle
08:54am, Wednesday, 06'th May 2026
New Nighttime Supplement Targets What Happens — or Fails to Happen — While You Sleep New Nighttime Supplement Targets What Happens — or Fails to Happen — While You Sleep
BioAdaptives® Announces Commercial Launch of MyndMed™ Following Successful Pilot Testing
11:48am, Tuesday, 07'th Oct 2025
Comprehensive cognitive-support formula now available online; company scaling production for anticipated Q4 demand Comprehensive cognitive-support formula now available online; company scaling product
BioAdaptives' MyndMed™ Receives Full Clearance from TruShield™, Meeting UFC and WADA Standards for Athlete Safety
11:54am, Wednesday, 20'th Aug 2025
Unique nootropic formula blends botanical extracts, amino acids and neuro-support nutrients to support balance, energy and resilience in athletes Unique nootropic formula blends botanical extracts, am
BioAdaptives Announces National Launch of NeuroRush™ — A Cutting-Edge Adaptogenic Nootropic for Mental Clarity, Focus, and Resilience
08:58am, Wednesday, 16'th Jul 2025
NeuroRush™ delivers a unique blend of adaptogens and nootropic herbs designed to enhance cognitive performance, stress response and long-term brain health, without dependency or burnout. NeuroRush�
BioAdaptives Announces National Launch of Pawpa™ Regen
10:31am, Tuesday, 24'th Jun 2025
Revolutionary Canine Supplement Promotes Regenerative Healing Through Stem Cell Activation Revolutionary Canine Supplement Promotes Regenerative Healing Through Stem Cell Activation
BioAdaptives® PawPa™ Regen Provides Breakthrough Stem Cell Support for Pets, Backed by Clinically Proven APBAR® Scale Improvements
09:15am, Wednesday, 28'th May 2025
Regen Dog Chews are crafted to the highest quality standards, recommended by veterinarians and proven safe with no adverse effects reported in clinical trials Regen Dog Chews are crafted to the highes
Zeranovia(TM) Weight Loss Product Shows Promising Results in Dosage Trial
09:15am, Thursday, 13'th Mar 2025
LAS VEGAS, March 13, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives Inc. (OTC: BDPT) today announced the successful completion of dosage trials for its innovative weight loss product, Zeranovia™.
BioAdaptives Welcomes UFC Senior Executive Reed Harris to Its Board of Advisors
09:25am, Thursday, 06'th Feb 2025
Harris, the Senior Vice President of Athlete Development and Marketing at the Ultimate Fighting Championship, has a distinguished career spanning over 40 years Harris, the Senior Vice President of Ath
BioAdaptives Welcomes Mark Frissora, Acclaimed Business Leader, to Its Board of Directors
09:25am, Monday, 03'rd Feb 2025
Frissora is recognized for his ability to lead organizations through complex challenges and deliver sustained value creation Frissora is recognized for his ability to lead organizations through comple
This Wide Moat ETF Could Be 2025 Star
09:20am, Tuesday, 10'th Dec 2024
Smaller stocks and related ETFs have found a groove since last month's presidential election. But performances across that vast landscape haven't been uniform.
BioAdaptives, Inc. Launches Xcellara™ Stem Cell Activator – Harnessing Nature for Optimal Health
09:15am, Tuesday, 10'th Dec 2024
LAS VEGAS, Dec. 10, 2024 (GLOBE NEWSWIRE) -- via IBN – BioAdaptives, Inc. (OTC: BDPT) is thrilled to announce the launch of Xcellara™ Stem Cell Activator, a groundbreaking supplement that harnesse
BioAdaptives, Inc.'s Board of Directors Approves a One-for-One Stock Dividend
09:15am, Tuesday, 03'rd Dec 2024
LAS VEGAS, Dec. 03, 2024 (GLOBE NEWSWIRE) -- via IBN – BioAdaptives Inc. (OTC: BDPT) Board of Directors has approved a dividend to all common stockholders. They will receive matching shares for all
BioAdaptives, Inc. Announces Institutional Review Board Approval of a Human Clinical Trial for Zeranovia™
09:15am, Monday, 25'th Nov 2024
LAS VEGAS, Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN – BioAdaptives Inc. (OTC: BDPT) received approval today for a human clinical trial of its weight management product, Zeranovia™.
BioAdaptives, Inc. Announces 5 Unique Products Ready for Phased Entry Into the Nutritional Marketplace
07:09pm, Thursday, 21'st Nov 2024
LAS VEGAS, Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAdaptives Inc. (OTC: BDPT) ushered in a new direction by appointing James Keener as CEO on May 21, 2024. Previous management retired, and Keener began f
